Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome – still an open question?
Posted by rob on December 21, 2009 under Uncategorized | 
Comments are off for this article
Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome – still an open question?
Leuk Lymphoma. 2009 Dec 17;
Authors: Rüping MJ, Vehreschild JJ, Cornely OA
In this review, we aim to compare different early treatment strategies of invasive fungal diseases in patients undergoing induction chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Three treatment approaches – prophylactic, empiric, and pre-emptive treatment – are subject to continuous discussion among physicians treating patients at risk. Considering the available clinical basis of evidence, we opt for antifungal prophylaxis with posaconazole 200 mg tid po as our primary prophylactic strategy, while the employment of pre-emptive treatment should be delayed until more accurate diagnostic tools become available. In addition to antifungal prophylaxis, empiric treatment with caspofungin or L-AmB may be administered to patients with fever resistant to broad-spectrum antibiotic treatment and without radiographic findings typical of invasive fungal disease.
PMID: 20017598 [PubMed - as supplied by publisher]